Niclosamide exerts its anti-cancer activity by targeting multiple pathways, including the Wnt/β-catenin, mammalian target of rapamycin complex 1 (mTORC1), signal transducers and activators of transcription 3 (STAT3), nuclear factor-kappa B (NF-κB), Notch pathways and damage to mitochondria2,3. This evidence concerns the gene STAT3 and cancer.